metformin has been researched along with Dyslipidemia in 68 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the efficacy and safety for metformin in treating antipsychotic-induced dyslipidemia." | 9.30 | [Metformin treatment of antipsychotic-induced dyslipidemia: analysis of two randomized, placebo-controlled trials]. ( Guo, W; Kang, D; Long, Y; Ou, J; Wang, X; Wu, R; Yang, Y; Zhao, J, 2019) |
| " In this study, data were pooled from two randomized, placebo-controlled trials, which were originally designed to examine the efficacy of metformin in treating antipsychotic-induced weight gain and other metabolic abnormalities." | 9.22 | Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. ( Chan, PK; Gao, KM; Guo, WB; Jin, H; Ou, JJ; Shao, P; Wu, RR; Zhang, FY; Zhao, JP, 2016) |
| "OBJECTIVE To compare the effect of short-term metformin and fenofibrate treatment, administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk factors, and monocyte cytokine release in type 2 diabetic patients with mixed dyslipidemia." | 9.14 | Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. ( Krysiak, R; Okopien, B; Pruski, M, 2009) |
| " The potential protective outcome of the antidiabetic and pleiotropic drug metformin against TAA-induced chronic kidney disease in association with the modulation of AMP-activated protein kinase (AMPK), oxidative stress, inflammation, dyslipidemia, and systemic hypertension has not been investigated before." | 8.31 | Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension. ( Al-Ani, B; Albawardi, A; Alqahtani, SM; Alshahrani, MY; Bayoumy, NM; Ebrahim, HA; Haidara, MA; Kamar, SS; ShamsEldeen, AM, 2023) |
| " To investigate the effects of metformin on myopathy risks when added to preexisting statin therapy in dyslipidemia patients, we performed a retrospective cohort study using the Korean national health insurance data in statin-treated dyslipidemia patients with or without concomitant metformin use." | 8.31 | Impact of metformin on statin-associated myopathy risks in dyslipidemia patients. ( Bak, K; Choi, YJ; Ko, M; Moon, S; Shin, S, 2023) |
| "The link between oxidative stress (ROS), apoptosis (p53) and fibrosis (collagen) in type 2 diabetes mellitus (T2DM)-induced cardiac injury in the presence and absence of the antidiabetic drug, metformin has not been investigated before." | 8.31 | Metformin ameliorates ROS-p53-collagen axis of fibrosis and dyslipidemia in type 2 diabetes mellitus-induced left ventricular injury. ( Al-Ani, B; Al-Hashem, F; Alzamil, NM; Bin-Jaliah, I; Dawood, AF; Haidara, MA; Hewett, PW; Kamar, SS; Latif, NSA; Shatoor, AS, 2023) |
| "This study establishes that betel nut induces dyslipidemia through its alkaloid, arecoline by inhibition of AMPK (Thr-172) and activation of ACC (Ser-79) and highlights the therapeutic potential of metformin for treatment of betel-nut induced carcinogenesis, indicating the repurposing of the old drug in a new avenue." | 7.91 | Treatment with the anti-diabetic drug metformin ameliorates betel-nut induced carcinogenesis in a murine model. ( Choudhury, Y; Laskar, J; Sengupta, M, 2019) |
| " The aim of this study is to investigate the effect of AA extract on oxidative stress and dyslipidemia in diabetic rats induced by alloxan." | 7.85 | Effect of hydroalcoholic Allium ampeloprasum extract on oxidative stress, diabetes mellitus and dyslipidemia in alloxan-induced diabetic rats. ( Heidarian, E; Kheiri, S; Rafieian-Kopaei, M; Rahimi-Madiseh, M, 2017) |
| " The present study aimed to evaluate the comparative effects of sodium butyrate (NaB) and metformin on the glucose homeostasis, insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat." | 7.83 | Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: A comparative study with metformin. ( Jena, G; Khan, S, 2016) |
| "A cross-sectional research was performed and 130 subjects with dyslipidemia and overweight/obese were enrolled and randomly assigned into combined group (20 mg of atorvastatin daily plus 500 mg of metformin twice daily) and control group (20 mg of atorvastatin daily)." | 7.83 | Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration. ( Hao, Z; Li, G; Liao, H; Liu, Y; Xiao, C; Zheng, D, 2016) |
| "To determine the effects of metformin therapy in children with metabolic syndrome (MS)." | 7.81 | Metformin treatment improves weight and dyslipidemia in children with metabolic syndrome. ( Ashraf, AP; Luong, DQ; Oster, R, 2015) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 7.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| "7%) stopped metformin therapy due to excessive anorexia." | 7.74 | Treatment of white coat hypertension with metformin. ( Camci, C; Helvaci, MR; Sevinc, A; Yalcin, A, 2008) |
| " The aim of this study was to evaluate the effects of rosuvastatin and metformin on inflammation and oxidative stress in patients with hypertension and dyslipidemia." | 7.74 | [Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia]. ( Alvarez-Aguilar, C; Gómez-García, A; Martínez Torres, G; Ortega-Pierres, LE; Rodríguez-Ayala, E, 2007) |
| "A total of 288 type 2 diabetes patients completed this double-blind parallel study (187 men, 101 women; age [mean ± SD], 59 ± 10 years; body mass index, 32." | 6.76 | PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. ( Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D, 2011) |
| "To examine the efficacy and safety for metformin in treating antipsychotic-induced dyslipidemia." | 5.30 | [Metformin treatment of antipsychotic-induced dyslipidemia: analysis of two randomized, placebo-controlled trials]. ( Guo, W; Kang, D; Long, Y; Ou, J; Wang, X; Wu, R; Yang, Y; Zhao, J, 2019) |
| " In this study, data were pooled from two randomized, placebo-controlled trials, which were originally designed to examine the efficacy of metformin in treating antipsychotic-induced weight gain and other metabolic abnormalities." | 5.22 | Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. ( Chan, PK; Gao, KM; Guo, WB; Jin, H; Ou, JJ; Shao, P; Wu, RR; Zhang, FY; Zhao, JP, 2016) |
| "OBJECTIVE To compare the effect of short-term metformin and fenofibrate treatment, administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk factors, and monocyte cytokine release in type 2 diabetic patients with mixed dyslipidemia." | 5.14 | Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. ( Krysiak, R; Okopien, B; Pruski, M, 2009) |
| "Due to the very high prevalences of excess weight and probably many associated disorders with the excess weight, including IGT or DM, WCH or HT, and dyslipidemia, above the age of 50 years, and the detected significant benefits of metformin on all of the above parameters, metformin treatment should be initiated in patients with excess weight in their fifties." | 5.13 | Metformin and parameters of physical health. ( Borazan, A; Helvaci, MR; Kaya, H; Ozer, C; Seyhanli, M; Yalcin, A, 2008) |
| " The potential protective outcome of the antidiabetic and pleiotropic drug metformin against TAA-induced chronic kidney disease in association with the modulation of AMP-activated protein kinase (AMPK), oxidative stress, inflammation, dyslipidemia, and systemic hypertension has not been investigated before." | 4.31 | Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension. ( Al-Ani, B; Albawardi, A; Alqahtani, SM; Alshahrani, MY; Bayoumy, NM; Ebrahim, HA; Haidara, MA; Kamar, SS; ShamsEldeen, AM, 2023) |
| " To investigate the effects of metformin on myopathy risks when added to preexisting statin therapy in dyslipidemia patients, we performed a retrospective cohort study using the Korean national health insurance data in statin-treated dyslipidemia patients with or without concomitant metformin use." | 4.31 | Impact of metformin on statin-associated myopathy risks in dyslipidemia patients. ( Bak, K; Choi, YJ; Ko, M; Moon, S; Shin, S, 2023) |
| "The link between oxidative stress (ROS), apoptosis (p53) and fibrosis (collagen) in type 2 diabetes mellitus (T2DM)-induced cardiac injury in the presence and absence of the antidiabetic drug, metformin has not been investigated before." | 4.31 | Metformin ameliorates ROS-p53-collagen axis of fibrosis and dyslipidemia in type 2 diabetes mellitus-induced left ventricular injury. ( Al-Ani, B; Al-Hashem, F; Alzamil, NM; Bin-Jaliah, I; Dawood, AF; Haidara, MA; Hewett, PW; Kamar, SS; Latif, NSA; Shatoor, AS, 2023) |
| " Metformin and renin-angiotensin system blockers were negatively associated with albuminuria and chronic kidney disease stages (p < 0." | 4.02 | Diabetic kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study. ( Abdulraheem, AM; Abufaraj, M; Al-Sabbagh, MQ; Albtoosh, A; Aljabiri, H; Arabiat, M; Farah, RI; Momani, MS, 2021) |
| "This study establishes that betel nut induces dyslipidemia through its alkaloid, arecoline by inhibition of AMPK (Thr-172) and activation of ACC (Ser-79) and highlights the therapeutic potential of metformin for treatment of betel-nut induced carcinogenesis, indicating the repurposing of the old drug in a new avenue." | 3.91 | Treatment with the anti-diabetic drug metformin ameliorates betel-nut induced carcinogenesis in a murine model. ( Choudhury, Y; Laskar, J; Sengupta, M, 2019) |
| " The aim of this study is to investigate the effect of AA extract on oxidative stress and dyslipidemia in diabetic rats induced by alloxan." | 3.85 | Effect of hydroalcoholic Allium ampeloprasum extract on oxidative stress, diabetes mellitus and dyslipidemia in alloxan-induced diabetic rats. ( Heidarian, E; Kheiri, S; Rafieian-Kopaei, M; Rahimi-Madiseh, M, 2017) |
| "A cross-sectional research was performed and 130 subjects with dyslipidemia and overweight/obese were enrolled and randomly assigned into combined group (20 mg of atorvastatin daily plus 500 mg of metformin twice daily) and control group (20 mg of atorvastatin daily)." | 3.83 | Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration. ( Hao, Z; Li, G; Liao, H; Liu, Y; Xiao, C; Zheng, D, 2016) |
| " The present study aimed to evaluate the comparative effects of sodium butyrate (NaB) and metformin on the glucose homeostasis, insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat." | 3.83 | Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: A comparative study with metformin. ( Jena, G; Khan, S, 2016) |
| "To determine the effects of metformin therapy in children with metabolic syndrome (MS)." | 3.81 | Metformin treatment improves weight and dyslipidemia in children with metabolic syndrome. ( Ashraf, AP; Luong, DQ; Oster, R, 2015) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 3.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| "7%) stopped metformin therapy due to excessive anorexia." | 3.74 | Treatment of white coat hypertension with metformin. ( Camci, C; Helvaci, MR; Sevinc, A; Yalcin, A, 2008) |
| " The aim of this study was to evaluate the effects of rosuvastatin and metformin on inflammation and oxidative stress in patients with hypertension and dyslipidemia." | 3.74 | [Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia]. ( Alvarez-Aguilar, C; Gómez-García, A; Martínez Torres, G; Ortega-Pierres, LE; Rodríguez-Ayala, E, 2007) |
| "In participants with type 2 diabetes, the incidences of microvascular complications and death were not materially different among the four treatment groups." | 3.11 | Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. ( Bebu, I; Burch, HB; Buse, JB; Cherrington, AL; Fortmann, SP; Green, JB; Kahn, SE; Kirkman, MS; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Phillips, LS; Pop-Busui, R; Steffes, M; Tiktin, M; Tripputi, M; Wexler, DJ; Younes, N, 2022) |
| "A total of 288 type 2 diabetes patients completed this double-blind parallel study (187 men, 101 women; age [mean ± SD], 59 ± 10 years; body mass index, 32." | 2.76 | PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. ( Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D, 2011) |
| "Type 2 diabetes mellitus is associated with a marked increase in the risk of coronary heart disease (CHD) or stroke (by a factor of two to three compared with non-diabetic patients), and cardiovascular disease (CVD) accounts for the majority of deaths among patients with diabetes." | 2.73 | Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients. ( Balasubramanian, R; Baliga, VP; Bolmall, C; Kathale, A; Nagraj, LM; Nayak, UP; Periyandavar, I; Sharma, A; Varadharajan, S, 2008) |
| "Statins have a primary role in the treatment of dyslipidemia in people with type 2 diabetes, defined as triglyceride levels >200 mg/dl and HDL cholesterol levels <40 mg/dL." | 2.55 | Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. ( Anabtawi, A; Miles, JM; Moriarty, PM, 2017) |
| "The link between NAFLD/NASH and PCOS is not just a coincidence." | 2.53 | Hepatic manifestations of women with polycystic ovary syndrome. ( Chen, MJ; Ho, HN, 2016) |
| "Dyslipidemia is manageable via statin treatment, while the anti-diabetic drug metformin would prevent hyperglycemia." | 2.50 | mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. ( De Loof, H; De Meyer, GRY; Martinet, W, 2014) |
| "Over 2." | 2.48 | Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program. ( Goldberg, RB; Mather, K, 2012) |
| "Among participants who had onset of type 2 diabetes in youth, the risk of complications, including microvascular complications, increased steadily over time and affected most participants by the time of young adulthood." | 1.62 | Long-Term Complications in Youth-Onset Type 2 Diabetes. ( Bjornstad, P; Caprio, S; Drews, KL; Gubitosi-Klug, R; Nathan, DM; Tesfaldet, B; Tryggestad, J; White, NH; Zeitler, P, 2021) |
| "no comorbidities) but more likely in congestive heart failure (OR 1." | 1.56 | Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed? ( Bell, JS; Ilomäki, J; Keen, CS; Magliano, DJ; Shaw, JE; Wood, SJ, 2020) |
| "Malaria is a major parasitic disease of humans and is a health public problem that affects more than 100 countries." | 1.51 | Plasmodium Infection Induces Dyslipidemia and a Hepatic Lipogenic State in the Host through the Inhibition of the AMPK-ACC Pathway. ( Araujo, MFC; Atella, GC; Atella, TC; da Rocha, I; Imperio, GED; Kluck, GEG; Miranda, KR; Wendt, CHC, 2019) |
| "Non‑alcoholic fatty liver disease (NAFLD), which affects approximately one‑third of the general population, has become a global health problem." | 1.48 | Inhibition of CCL19 benefits non‑alcoholic fatty liver disease by inhibiting TLR4/NF‑κB‑p65 signaling. ( Gao, S; Huang, D; Huang, J; Tong, P; Wang, Y; Wu, X; Yue, Y; Zhao, J, 2018) |
| "To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as little is known about the influence of T2DM diagnosis on the receipt of such treatment in men with localized PCa." | 1.48 | Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer. ( Adolfsson, J; Crawley, D; Garmo, H; Holmberg, L; Rudman, S; Stattin, P; Van Hemelrijck, M; Zethelius, B, 2018) |
| "Metformin has a greater impact on BMI in responders of metformin compared to nonresponders." | 1.43 | The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin. ( Alizadeh, A; Kashi, Z; Kianmehr, A; Mahrooz, A, 2016) |
| "Metformin treatment improved these alterations." | 1.38 | Improvement of metabolic parameters and vascular function by metformin in obese non-diabetic rats. ( Akamine, EH; Carvalho, MH; Filgueira, FP; Fortes, ZB; Hagihara, GN; Lobato, NS; Pariz, JR; Tostes, RC, 2012) |
| "The prevalence of type 2 diabetes in Thailand is 9." | 1.36 | Thailand Diabetic Registry cohort: predicting death in Thai diabetic patients and causes of death. ( Benjasuratwong, Y; Bunnag, P; Chetthakul, T; Deerochanawong, C; Komoltri, C; Kosachunhanun, N; Krittiyawong, S; Leelawatana, R; Mongkolsomlit, S; Ngarmukos, C; Plengvidhya, N; Pratipanawatr, T; Rawdaree, P; Suwanwalaikorn, S, 2010) |
| "Type 2 diabetes mellitus is a heterogeneous condition in which the clinical manifestation of hyperglycemia is a reflection of the impaired balance between insulin sensitivity and insulin secretion." | 1.33 | Type 2 diabetes mellitus in youth: the complete picture to date. ( Arslanian, S; Bacha, F; Gungor, N; Hannon, T; Libman, I, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (17.65) | 29.6817 |
| 2010's | 44 (64.71) | 24.3611 |
| 2020's | 12 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, A | 1 |
| Sharma, S | 1 |
| Tripathi, VD | 1 |
| Maurya, RA | 1 |
| Srivastava, SP | 2 |
| Bhatia, G | 1 |
| Tamrakar, AK | 1 |
| Srivastava, AK | 3 |
| Raza, S | 1 |
| Srivastava, DS | 1 |
| Haq, W | 1 |
| Katti, SB | 1 |
| Aggarwal, H | 1 |
| Pathak, P | 1 |
| Kumar, Y | 1 |
| Jagavelu, K | 1 |
| Dikshit, M | 1 |
| Majeed, M | 1 |
| Mundkur, L | 1 |
| Paulose, S | 1 |
| Nagabhushanam, K | 1 |
| Mahmoud, MF | 1 |
| Elmaghraby, AM | 1 |
| Ali, N | 1 |
| Mostafa, I | 1 |
| El-Shazly, AM | 1 |
| Abdelfattah, MAO | 1 |
| Sobeh, M | 1 |
| Nathan, DM | 2 |
| Lachin, JM | 1 |
| Bebu, I | 1 |
| Burch, HB | 1 |
| Buse, JB | 1 |
| Cherrington, AL | 1 |
| Fortmann, SP | 1 |
| Green, JB | 1 |
| Kahn, SE | 1 |
| Kirkman, MS | 1 |
| Krause-Steinrauf, H | 1 |
| Larkin, ME | 1 |
| Phillips, LS | 1 |
| Pop-Busui, R | 1 |
| Steffes, M | 1 |
| Tiktin, M | 1 |
| Tripputi, M | 1 |
| Wexler, DJ | 1 |
| Younes, N | 1 |
| Alanazi, J | 3 |
| Unnisa, A | 3 |
| Ahmad, S | 3 |
| Itumalla, R | 3 |
| Alanazi, M | 3 |
| Alharby, TN | 3 |
| Anwar, S | 3 |
| Younes, KM | 3 |
| Hussain, T | 3 |
| Hussain, A | 3 |
| Elamine, BA | 3 |
| Mohamed, OA | 3 |
| Alshahrani, MY | 1 |
| Ebrahim, HA | 1 |
| Alqahtani, SM | 1 |
| Bayoumy, NM | 1 |
| Kamar, SS | 2 |
| ShamsEldeen, AM | 1 |
| Haidara, MA | 2 |
| Al-Ani, B | 2 |
| Albawardi, A | 1 |
| Bak, K | 1 |
| Moon, S | 1 |
| Ko, M | 1 |
| Choi, YJ | 1 |
| Shin, S | 1 |
| Wood, SJ | 1 |
| Magliano, DJ | 1 |
| Bell, JS | 1 |
| Shaw, JE | 1 |
| Keen, CS | 1 |
| Ilomäki, J | 1 |
| Kluck, GEG | 1 |
| Wendt, CHC | 1 |
| Imperio, GED | 1 |
| Araujo, MFC | 1 |
| Atella, TC | 1 |
| da Rocha, I | 1 |
| Miranda, KR | 1 |
| Atella, GC | 1 |
| Laskar, J | 1 |
| Sengupta, M | 1 |
| Choudhury, Y | 1 |
| Yang, Y | 1 |
| Wang, X | 1 |
| Kang, D | 1 |
| Long, Y | 1 |
| Ou, J | 1 |
| Guo, W | 1 |
| Zhao, J | 2 |
| Wu, R | 1 |
| Majore, S | 1 |
| Agolini, E | 1 |
| Micale, L | 1 |
| Pascolini, G | 1 |
| Zuppi, P | 1 |
| Cocciadiferro, D | 1 |
| Morlino, S | 1 |
| Mattiuzzo, M | 1 |
| Valiante, M | 1 |
| Castori, M | 1 |
| Novelli, A | 1 |
| Grammatico, P | 1 |
| Alzamil, NM | 1 |
| Hewett, PW | 1 |
| Al-Hashem, F | 1 |
| Bin-Jaliah, I | 1 |
| Shatoor, AS | 1 |
| Latif, NSA | 1 |
| Dawood, AF | 1 |
| Farah, RI | 1 |
| Al-Sabbagh, MQ | 1 |
| Momani, MS | 1 |
| Albtoosh, A | 1 |
| Arabiat, M | 1 |
| Abdulraheem, AM | 1 |
| Aljabiri, H | 1 |
| Abufaraj, M | 1 |
| Bjornstad, P | 1 |
| Drews, KL | 1 |
| Caprio, S | 1 |
| Gubitosi-Klug, R | 1 |
| Tesfaldet, B | 1 |
| Tryggestad, J | 1 |
| White, NH | 1 |
| Zeitler, P | 1 |
| Crawley, D | 1 |
| Garmo, H | 1 |
| Rudman, S | 1 |
| Stattin, P | 1 |
| Zethelius, B | 1 |
| Holmberg, L | 1 |
| Adolfsson, J | 1 |
| Van Hemelrijck, M | 1 |
| Anabtawi, A | 1 |
| Moriarty, PM | 1 |
| Miles, JM | 1 |
| Allin, KH | 1 |
| Tremaroli, V | 1 |
| Caesar, R | 1 |
| Jensen, BAH | 1 |
| Damgaard, MTF | 1 |
| Bahl, MI | 1 |
| Licht, TR | 1 |
| Hansen, TH | 1 |
| Nielsen, T | 1 |
| Dantoft, TM | 1 |
| Linneberg, A | 1 |
| Jørgensen, T | 1 |
| Vestergaard, H | 1 |
| Kristiansen, K | 1 |
| Franks, PW | 2 |
| Hansen, T | 1 |
| Bäckhed, F | 1 |
| Pedersen, O | 1 |
| van Stee, MF | 1 |
| de Graaf, AA | 1 |
| Groen, AK | 1 |
| Yang, P | 1 |
| Liu, X | 1 |
| Gao, J | 1 |
| Qu, S | 1 |
| Zhang, M | 1 |
| Stokes, WA | 1 |
| Eguchi, M | 1 |
| Amini, A | 1 |
| Hararah, MK | 1 |
| Ding, D | 1 |
| McDermott, JD | 1 |
| Bradley, CJ | 1 |
| Karam, SD | 1 |
| Wang, Y | 1 |
| Wu, X | 1 |
| Tong, P | 1 |
| Yue, Y | 1 |
| Gao, S | 1 |
| Huang, D | 1 |
| Huang, J | 1 |
| Bozdag, G | 1 |
| Yildiz, BO | 1 |
| Arayne, MS | 1 |
| Sultana, N | 1 |
| Tabassum, A | 1 |
| Hung, YC | 1 |
| Lin, CC | 1 |
| Wang, TY | 1 |
| Chang, MP | 1 |
| Sung, FC | 1 |
| Chen, CC | 1 |
| Geerling, JJ | 1 |
| Boon, MR | 1 |
| van der Zon, GC | 1 |
| van den Berg, SA | 1 |
| van den Hoek, AM | 1 |
| Lombès, M | 1 |
| Princen, HM | 1 |
| Havekes, LM | 1 |
| Rensen, PC | 1 |
| Guigas, B | 1 |
| Gouni-Berthold, I | 1 |
| Berthold, HK | 1 |
| Fiorentino, TV | 1 |
| Sesti, G | 1 |
| Martinet, W | 1 |
| De Loof, H | 1 |
| De Meyer, GRY | 1 |
| Ibáñez, L | 1 |
| Ong, KK | 1 |
| López-Bermejo, A | 1 |
| Dunger, DB | 1 |
| de Zegher, F | 1 |
| Konrad, K | 1 |
| Datz, N | 1 |
| Engelsberger, I | 1 |
| Grulich-Henn, J | 1 |
| Hoertenhuber, T | 1 |
| Knauth, B | 1 |
| Meissner, T | 1 |
| Wiegand, S | 1 |
| Woelfle, J | 1 |
| Holl, RW | 1 |
| Luong, DQ | 1 |
| Oster, R | 1 |
| Ashraf, AP | 1 |
| Kalina, MA | 1 |
| Wilczek, M | 1 |
| Kalina-Faska, B | 1 |
| Skała-Zamorowska, E | 1 |
| Mandera, M | 1 |
| Małecka Tendera, E | 1 |
| Wang, B | 1 |
| Choudhry, NK | 1 |
| Gagne, JJ | 1 |
| Landon, J | 1 |
| Kesselheim, AS | 1 |
| Wu, RR | 1 |
| Zhang, FY | 1 |
| Gao, KM | 1 |
| Ou, JJ | 1 |
| Shao, P | 1 |
| Jin, H | 1 |
| Guo, WB | 1 |
| Chan, PK | 1 |
| Zhao, JP | 1 |
| Kashi, Z | 1 |
| Mahrooz, A | 1 |
| Kianmehr, A | 1 |
| Alizadeh, A | 1 |
| Chen, MJ | 1 |
| Ho, HN | 1 |
| Kalra, S | 1 |
| Gupta, Y | 1 |
| Kishor, K | 1 |
| Hao, Z | 1 |
| Liu, Y | 1 |
| Liao, H | 1 |
| Zheng, D | 1 |
| Xiao, C | 1 |
| Li, G | 1 |
| Khan, S | 1 |
| Jena, G | 1 |
| Antu, KA | 1 |
| Riya, MP | 1 |
| Nair, A | 1 |
| Mishra, A | 1 |
| Raghu, KG | 1 |
| Rahimi-Madiseh, M | 1 |
| Heidarian, E | 1 |
| Kheiri, S | 1 |
| Rafieian-Kopaei, M | 1 |
| Hussain, M | 1 |
| Atif, MA | 1 |
| Ghafoor, MB | 1 |
| Balasubramanian, R | 1 |
| Varadharajan, S | 1 |
| Kathale, A | 1 |
| Nagraj, LM | 1 |
| Periyandavar, I | 1 |
| Nayak, UP | 1 |
| Sharma, A | 1 |
| Bolmall, C | 1 |
| Baliga, VP | 1 |
| Vuppalanchi, R | 1 |
| Chalasani, N | 1 |
| Helvaci, MR | 2 |
| Sevinc, A | 1 |
| Camci, C | 1 |
| Yalcin, A | 2 |
| Pruski, M | 1 |
| Krysiak, R | 1 |
| Okopien, B | 1 |
| Jadeja, RN | 1 |
| Thounaojam, MC | 1 |
| Patel, VB | 1 |
| Devkar, RV | 1 |
| Ramachandran, AV | 1 |
| Pratipanawatr, T | 1 |
| Rawdaree, P | 1 |
| Chetthakul, T | 1 |
| Bunnag, P | 1 |
| Ngarmukos, C | 1 |
| Benjasuratwong, Y | 1 |
| Leelawatana, R | 1 |
| Kosachunhanun, N | 1 |
| Plengvidhya, N | 1 |
| Deerochanawong, C | 1 |
| Suwanwalaikorn, S | 1 |
| Krittiyawong, S | 1 |
| Mongkolsomlit, S | 1 |
| Komoltri, C | 1 |
| Pfützner, A | 1 |
| Schöndorf, T | 1 |
| Tschöpe, D | 1 |
| Lobmann, R | 1 |
| Merke, J | 1 |
| Müller, J | 1 |
| Lehmann, U | 1 |
| Fuchs, W | 1 |
| Forst, T | 1 |
| Adeneye, AA | 1 |
| Agbaje, EO | 1 |
| Olagunju, JA | 1 |
| Boguszewski, MC | 1 |
| Mericq, V | 1 |
| Bergada, I | 1 |
| Damiani, D | 1 |
| Belgorosky, A | 1 |
| Gunczler, P | 1 |
| Ortiz, T | 1 |
| Llano, M | 1 |
| Domené, HM | 1 |
| Calzada-León, R | 1 |
| Blanco, A | 1 |
| Barrientos, M | 1 |
| Procel, P | 1 |
| Lanes, R | 1 |
| Jaramillo, O | 1 |
| Ashraf, R | 1 |
| Khan, RA | 1 |
| Ashraf, I | 1 |
| Lobato, NS | 1 |
| Filgueira, FP | 1 |
| Hagihara, GN | 1 |
| Akamine, EH | 1 |
| Pariz, JR | 1 |
| Tostes, RC | 1 |
| Carvalho, MH | 1 |
| Fortes, ZB | 1 |
| Goldberg, RB | 2 |
| Mather, K | 1 |
| Pollin, TI | 1 |
| Isakova, T | 1 |
| Jablonski, KA | 1 |
| de Bakker, PI | 1 |
| Taylor, A | 1 |
| McAteer, J | 1 |
| Pan, Q | 1 |
| Horton, ES | 1 |
| Delahanty, LM | 1 |
| Altshuler, D | 1 |
| Shuldiner, AR | 1 |
| Florez, JC | 1 |
| Motshakeri, M | 1 |
| Ebrahimi, M | 1 |
| Goh, YM | 1 |
| Matanjun, P | 1 |
| Mohamed, S | 1 |
| Carmina, E | 1 |
| Betteridge, DJ | 1 |
| Vergès, B | 1 |
| Gungor, N | 1 |
| Hannon, T | 1 |
| Libman, I | 1 |
| Bacha, F | 1 |
| Arslanian, S | 1 |
| Luque-Ramírez, M | 1 |
| Alvarez-Blasco, F | 1 |
| Botella-Carretero, JI | 1 |
| Martínez-Bermejo, E | 1 |
| Lasunción, MA | 1 |
| Escobar-Morreale, HF | 1 |
| Bradbury, RA | 1 |
| Samaras, K | 1 |
| Comaschi, M | 1 |
| Corsi, A | 1 |
| Di Pietro, C | 1 |
| Bellatreccia, A | 1 |
| Mariz, S | 1 |
| García-Moll, X | 1 |
| Gómez-García, A | 1 |
| Martínez Torres, G | 1 |
| Ortega-Pierres, LE | 1 |
| Rodríguez-Ayala, E | 1 |
| Alvarez-Aguilar, C | 1 |
| Kaya, H | 1 |
| Borazan, A | 1 |
| Ozer, C | 1 |
| Seyhanli, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study[NCT01794143] | Phase 3 | 5,047 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Feasibility of the FreeStyle Libre Continuous Glucose Monitoring System in Youth With Type 2 Diabetes (FREE_CGM)[NCT06089070] | 30 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | |||
| Long-term Post-Intervention Follow-up of the TODAY Cohort (Treatment Options for Type 2 Diabetes in Youth and Adolescents)[NCT02310724] | 517 participants (Actual) | Observational | 2014-03-01 | Completed | |||
| TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study of the TODAY Clinical Trial Cohort[NCT01364350] | 550 participants (Actual) | Observational | 2011-03-31 | Completed | |||
| Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study[NCT04081571] | 1,080 participants (Anticipated) | Observational | 2019-04-01 | Recruiting | |||
| Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic Dyslipidemia[NCT00770653] | Phase 3 | 305 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Bioequivalence Study of 2 mg Cyproterone Acetate and 0.035 mg Ethinyl Estradiol in Indonesian Healthy Females[NCT04964193] | 24 participants (Actual) | Interventional | 2019-03-12 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change between Adiponectin collected at week 24 or final visit and Adiponectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | μg/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 6.79 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.72 |
The change between Diastolic Blood Pressure measured at week 24 or final visit and Diastolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -1.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.1 |
The change between the value of E-Selectin collected at week 24 or final visit and E-Selectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -3.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.5 |
The change between the 0.30 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 1.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.4 |
The change between the 0.60 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.4 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.5 |
The change between the 1.20 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.2 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.1 |
The change between the 12.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between the 3.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -.15 |
The change between the 30.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.5 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between the 6.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.1 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.4 |
The change between the 60.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between Fasting Glucose collected at week 24 or final visit and Fasting Glucose collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -21.6 |
| Glimepiride 2 mg and Metformin 850 mg BID | -21.1 |
The change between Fasting Intact Proinsulin collected at week 24 or final visit and Fasting Intact Proinsulin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | pmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -5.18 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.11 |
The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit and Glycosylated Hemoglobin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -0.83 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.95 |
The change between the value of High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at week 24 or final visit and High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/L (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -0.87 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.00 |
The change between the value of High Sensitivity C-reactive Protein collected at week 24 or final visit and High Sensitivity C-reactive Protein collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -0.21 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.04 |
The change between HDL-Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.4 |
The change between High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at week 24 or final visit and High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 0.1 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.3 |
The change between Low-Density Lipoprotein Cholesterol collected at week 24 or final visit and Low-Density Lipoprotein Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 9.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | 11.2 |
The change between the value of Low-Density Lipoprotein Subfractions collected at week 24 or final visit and Low-Density Lipoprotein Subfractions collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 6.2 |
| Glimepiride 2 mg and Metformin 850 mg BID | 6.1 |
The change between the value of Baseline in Matrix Metallo Proteinase-9 collected at week 24 or final visit and Baseline in Matrix Metallo Proteinase-9 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 31.4 |
| Glimepiride 2 mg and Metformin 850 mg BID | 51.6 |
The change between the value of Nitrotyrosine collected at week 24 or final visit and Nitrotyrosine collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -2.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | 32.5 |
The change between the value of Platelet Function by PFA 100 collected at week 24 or final visit and Platelet Function by PFA 100 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | sec (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -30.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.0 |
The change between the value of Soluble CD40 Ligand collected at week 24 or final visit and Soluble CD40 Ligand collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | pg/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -40.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | 102.4 |
The change between the value of Baseline in Soluble Intracellular Adhesion molecule at week 24 or final visit and Baseline in Soluble Intracellular Adhesion molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -13.0 |
| Glimepiride 2 mg and Metformin 850 mg BID | -3.2 |
The change between the value of Soluble Vascular Cell Adhesion Molecule collected at week 24 or final visit and Soluble Vascular Cell Adhesion Molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 11.6 |
| Glimepiride 2 mg and Metformin 850 mg BID | 3.3 |
The change between Systolic Blood Pressure measured at week 24 or final visit and Systolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -2.5 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.5 |
The change between the value of Thromboxane B2 collected at week 24 or final visit and Thromboxane B2 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | pg/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -216.4 |
| Glimepiride 2 mg and Metformin 850 mg BID | 527.8 |
The change between the value of Triglycerides collected at week 24 or final visit and Triglycerides collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -40.9 |
| Glimepiride 2 mg and Metformin 850 mg BID | -16.7 |
The change between the value of Von-Willebrand Factor collected at week 24 or final visit and Von-Willebrand Factor collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -19.5 |
| Glimepiride 2 mg and Metformin 850 mg BID | 1.4 |
The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | participants (Number) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 136 |
| Glimepiride 2 mg and Metformin 850 mg BID | 137 |
The increase in High-Density Lipoprotein (HDL) Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.2 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.3 |
Area Under Curve from 0 to 72 hours (AUCt) (NCT04964193)
Timeframe: before dosing (0 h) and at 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 15, 24, 36, 48 and 72 hours after dosing
| Intervention | pg*hr/mL (Mean) | |
|---|---|---|
| AUC0-t of Cyproterone Acetate | AUC0-t of Ethinyl Estradiol | |
| Diane-35 Sugar-coated Tablet | 127.54 | 842.56 |
| Elzsa Film-coated Tablet | 132.56 | 870.45 |
Maximum plasma concentration (Cmax) (NCT04964193)
Timeframe: before dosing (0 h) and at 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 15, 24, 36, 48 and 72 hours after dosing
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Cmax of Cyproterone Acetate | Cmax of Ethinyl Estradiol | |
| Diane-35 Sugar-coated Tablet | 16.20 | 93.61 |
| Elzsa Film-coated Tablet | 17.39 | 103.69 |
11 reviews available for metformin and Dyslipidemia
| Article | Year |
|---|---|
Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Glucagon-Like Peptid | 2017 |
Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy.
Topics: Animals; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Interac | 2018 |
Interventions for the metabolic dysfunction in polycystic ovary syndrome.
Topics: Diabetes Mellitus; Diet; Dyslipidemias; Exercise; Female; Humans; Hypoglycemic Agents; Metformin; Ob | 2013 |
Pharmacologic therapy for cardiovascular risk reduction in patients with the metabolic syndrome.
Topics: Acarbose; Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Humans; Hydroxymethylglutaryl-C | 2014 |
mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques.
Topics: Absorbable Implants; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Cholesterol; Clinica | 2014 |
Hepatic manifestations of women with polycystic ovary syndrome.
Topics: Alanine Transaminase; Androgen Antagonists; Aspartate Aminotransferases; Contraceptives, Oral, Hormo | 2016 |
The cardiovascular phenotype: impact on choice of glucose- lowering therapy.
Topics: Acarbose; Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; | 2016 |
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type | 2009 |
Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; | 2012 |
PCOS: metabolic impact and long-term management.
Topics: Adolescent; Adult; Antihypertensive Agents; Cardiovascular Diseases; Child; Comorbidity; Diabetes Me | 2012 |
Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost?
Topics: Antiretroviral Therapy, Highly Active; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, | 2008 |
13 trials available for metformin and Dyslipidemia
| Article | Year |
|---|---|
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
Topics: Albuminuria; Blood Glucose; Cardiovascular Diseases; Comparative Effectiveness Research; Diabetes Co | 2022 |
Significance of Orlistat in management of dyslipidemia, systolic blood pressure and body mass index.
Topics: Blood Pressure; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dysl | 2022 |
Significance of Orlistat in management of dyslipidemia, systolic blood pressure and body mass index.
Topics: Blood Pressure; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dysl | 2022 |
Significance of Orlistat in management of dyslipidemia, systolic blood pressure and body mass index.
Topics: Blood Pressure; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dysl | 2022 |
Significance of Orlistat in management of dyslipidemia, systolic blood pressure and body mass index.
Topics: Blood Pressure; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dysl | 2022 |
[Metformin treatment of antipsychotic-induced dyslipidemia: analysis of two randomized, placebo-controlled trials].
Topics: Antipsychotic Agents; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; | 2019 |
Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Weight; Double-Blind Method; Dyslipidemias; Female; | 2016 |
Beneficial effects of sitagliptin and metformin in non-diabetic hypertensive and dyslipidemic patients.
Topics: Adult; Antihypertensive Agents; Biomarkers; Blood Pressure; Dipeptidyl-Peptidase IV Inhibitors; Dysl | 2016 |
Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2008 |
Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Combined Modality Therapy; Cytokines; Di | 2009 |
PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Topics: Adiponectin; Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; | 2011 |
Garlic (Allium sativum) supplementation with standard antidiabetic agent provides better diabetic control in type 2 diabetes patients.
Topics: Adult; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dr | 2011 |
Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; | 2005 |
Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
Topics: Administration, Oral; Adult; Androgen Antagonists; Androgens; Blood Glucose; Cardiovascular Diseases | 2007 |
The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Topics: Aged; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dru | 2008 |
Metformin and parameters of physical health.
Topics: Age Factors; Aged; Blood Glucose; Diabetes Mellitus; Dose-Response Relationship, Drug; Dyslipidemias | 2008 |
44 other studies available for metformin and Dyslipidemia
| Article | Year |
|---|---|
Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Design; Dyslipidemias; Glycogen Phosphorylase; Hypogl | 2010 |
Thiazolidin-4-one and thiazinan-4-one derivatives analogous to rosiglitazone as potential antihyperglycemic and antidyslipidemic agents.
Topics: 3T3-L1 Cells; Animals; Blood Glucose; Cell Differentiation; Cell Line; Diabetes Mellitus, Type 2; Do | 2013 |
Modulation of Insulin Resistance, Dyslipidemia and Serum Metabolome in iNOS Knockout Mice following Treatment with Nitrite, Metformin, Pioglitazone, and a Combination of Ampicillin and Neomycin.
Topics: Ampicillin; Animals; Drug Therapy, Combination; Dyslipidemias; Glucose; Homeostasis; Hypoglycemic Ag | 2021 |
Novel
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dyslipidemias; Glycated Hemoglobin; Humans; Hydrolyzable T | 2022 |
Black pepper oil (Piper nigrum L.) mitigates dexamethasone induced pancreatic damage via modulation of oxidative and nitrosative stress.
Topics: Animals; Blood Glucose; COVID-19 Drug Treatment; Dexamethasone; Dyslipidemias; Fibrosis; Insulin Res | 2022 |
Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension.
Topics: AMP-Activated Protein Kinases; Animals; Down-Regulation; Dyslipidemias; Fibrosis; Hypertension; Infl | 2023 |
Impact of metformin on statin-associated myopathy risks in dyslipidemia patients.
Topics: Cohort Studies; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic | 2023 |
Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed?
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Australia; Cerebrovascular Disorders; Comorbidity; Diab | 2020 |
Plasmodium Infection Induces Dyslipidemia and a Hepatic Lipogenic State in the Host through the Inhibition of the AMPK-ACC Pathway.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Cholesterol; Dyslipidemias; Fatty Ac | 2019 |
Treatment with the anti-diabetic drug metformin ameliorates betel-nut induced carcinogenesis in a murine model.
Topics: AMP-Activated Protein Kinases; Animals; Areca; Arecoline; Carcinogenesis; Disease Models, Animal; Dy | 2019 |
Clinical presentation and molecular characterization of a novel patient with variant POC1A-related syndrome.
Topics: Acanthosis Nigricans; Adult; Age of Onset; Cell Cycle Proteins; Computer Simulation; Congenital Hype | 2021 |
Metformin ameliorates ROS-p53-collagen axis of fibrosis and dyslipidemia in type 2 diabetes mellitus-induced left ventricular injury.
Topics: Animals; Collagen; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dyslipidemias; Fibros | 2023 |
Diabetic kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study.
Topics: Age Factors; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Cross-Sectional Studies; Diabete | 2021 |
Long-Term Complications in Youth-Onset Type 2 Diabetes.
Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow- | 2021 |
Long-Term Complications in Youth-Onset Type 2 Diabetes.
Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow- | 2021 |
Long-Term Complications in Youth-Onset Type 2 Diabetes.
Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow- | 2021 |
Long-Term Complications in Youth-Onset Type 2 Diabetes.
Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow- | 2021 |
Long-Term Complications in Youth-Onset Type 2 Diabetes.
Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow- | 2021 |
Long-Term Complications in Youth-Onset Type 2 Diabetes.
Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow- | 2021 |
Long-Term Complications in Youth-Onset Type 2 Diabetes.
Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow- | 2021 |
Long-Term Complications in Youth-Onset Type 2 Diabetes.
Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow- | 2021 |
Long-Term Complications in Youth-Onset Type 2 Diabetes.
Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow- | 2021 |
Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer.
Topics: Aged; Aged, 80 and over; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypertension | 2018 |
Aberrant intestinal microbiota in individuals with prediabetes.
Topics: Aged; Animals; Anthropometry; Biomarkers; Blood Glucose; Case-Control Studies; Denmark; Diabetes Mel | 2018 |
Complete androgen insensitivity syndrome in a young woman with metabolic disorder and diabetes: A case report.
Topics: Amenorrhea; Androgen-Insensitivity Syndrome; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hydro | 2018 |
Survival impact and toxicity of metformin in head and neck cancer: An analysis of the SEER-Medicare dataset.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Cohort Studies; Combined | 2018 |
Inhibition of CCL19 benefits non‑alcoholic fatty liver disease by inhibiting TLR4/NF‑κB‑p65 signaling.
Topics: Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Animals; Aspartate Aminotransferases; Be | 2018 |
RP-LC simultaneous quantitation of co-administered drugs for (non-insulin dependent) diabetic mellitus induced dyslipidemia in active pharmaceutical ingredient, pharmaceutical formulations and human serum with UV-detector.
Topics: Adult; Anticholesteremic Agents; Calibration; Chromatography, Reverse-Phase; Diabetes Mellitus, Type | 2013 |
Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Cardiovascular Diseases; Cohort Studies; Comorbidity; Coronary Di | 2013 |
Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice.
Topics: Adipose Tissue, Brown; AMP-Activated Protein Kinases; Animals; Cells, Cultured; Cholesterol; Dyslipi | 2014 |
[Effects of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors].
Topics: Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; | 2013 |
Hyperinsulinaemic androgen excess in adolescent girls.
Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Human | 2014 |
Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria.
Topics: Adolescent; Austria; Body Mass Index; Child; Cohort Studies; Diabetes Mellitus, Type 1; Diabetic Ang | 2015 |
Metformin treatment improves weight and dyslipidemia in children with metabolic syndrome.
Topics: Adolescent; Body Mass Index; Body Weight; Child; Dyslipidemias; Humans; Hypoglycemic Agents; Metabol | 2015 |
Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience.
Topics: Adolescent; Carbohydrates; Child; Child, Preschool; Craniopharyngioma; Dyslipidemias; Female; Fenofi | 2015 |
Availability and utilization of cardiovascular fixed-dose combination drugs in the United States.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; D | 2015 |
The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.
Topics: Adult; Atorvastatin; Biological Transport; Blood Glucose; Blood Pressure; Body Mass Index; Cholester | 2016 |
Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration.
Topics: Adult; Atorvastatin; Cross-Sectional Studies; Drug Therapy, Combination; Dyslipidemias; Female; Huma | 2016 |
Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: A comparative study with metformin.
Topics: Acetylation; Adipose Tissue; Animals; Blood Glucose; Butyric Acid; Diabetes Mellitus, Experimental; | 2016 |
Symplocos cochinchinensis enhances insulin sensitivity via the down regulation of lipogenesis and insulin resistance in high energy diet rat model.
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diet, High-Fat; Dose-Response R | 2016 |
Effect of hydroalcoholic Allium ampeloprasum extract on oxidative stress, diabetes mellitus and dyslipidemia in alloxan-induced diabetic rats.
Topics: Allium; Alloxan; Animals; Antioxidants; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; | 2017 |
Treatment of white coat hypertension with metformin.
Topics: Adolescent; Adult; Aged; Anorexia; Appetite Depressants; Blood Glucose; Dyslipidemias; Female; Human | 2008 |
Protective effect of Clerodendron glandulosum extract against experimentally induced metabolic syndrome in rats.
Topics: Animals; Blood Pressure; Clerodendrum; Disease Models, Animal; Dyslipidemias; Insulin Resistance; Li | 2010 |
Thailand Diabetic Registry cohort: predicting death in Thai diabetic patients and causes of death.
Topics: Aged; Asian People; Cardiovascular Diseases; Cause of Death; Diabetes Complications; Diabetes Mellit | 2010 |
Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Disease Models, Animal; Dyslipidemias; Glyburide; Huma | 2011 |
Latin American consensus: children born small for gestational age.
Topics: Child, Preschool; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female | 2011 |
Improvement of metabolic parameters and vascular function by metformin in obese non-diabetic rats.
Topics: Acetylcholine; Animals; Blood Pressure; Body Weight; Disease Models, Animal; Dyslipidemias; Epoprost | 2012 |
Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program.
Topics: Adult; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dysli | 2012 |
Sargassum polycystum reduces hyperglycaemia, dyslipidaemia and oxidative stress via increasing insulin sensitivity in a rat model of type 2 diabetes.
Topics: Animals; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Di | 2013 |
Type 2 diabetes mellitus in youth: the complete picture to date.
Topics: Adolescent; Autoantibodies; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Diet; Dyslipid | 2005 |
[Inflammation, atherosclerosis, classic cardiovascular risk factors, biostatistics, clinical significance. Where are we?].
Topics: Acute Coronary Syndrome; Atherosclerosis; Biometry; Dyslipidemias; Fluorobenzenes; Humans; Hydroxyme | 2007 |
[Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia].
Topics: Analysis of Variance; Dyslipidemias; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutary | 2007 |